Health Condition 1: L100- Pemphigus vulgaris
Conditions
Interventions
Intervention1: Rituximab and Systemic Steroids Versus only Systemic Steroids: Rituximab is a chimeric monoclonal antibody that targets the CD20 molecule on B-cells.
IT IS FDA APPROVED IN MODERATE
however, there is limited data from the Indian subcontinent.
Protocol for Rituximab :
â?¢ Seperate IV line
â?¢ Pre medications before 30 minutes of giving rituximab infusion:
Inj. Dexona 2cc IV
Inj.
Sponsors
GMERS Medical College and Hospital Sola
Eligibility
Inclusion criteria
Inclusion criteria: Patients of above 18 years and of any gender , who willing to sign written informed consent.
Exclusion criteria
Exclusion criteria: Any patient with active bacterial, viral, invasive fungal infections. HIV reactive patients. Any haematological dyscrasia/ Bleeding tendency. Patients with history of any severe drug reaction in past. Patients with metabolic disturbances, cardiac disorders. Pregnancy and lactation. Patients or relatives â?? not willing to sign written informed consent.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| study any side effects in both groups.Timepoint: From initiation of treatment to 4 months | — |
Primary
| Measure | Time frame |
|---|---|
| we will evaluate for cumulative dose of systemic steroids & time require to reach minimum dose (10 mg prednisolone daily) in each patients after 4 monthsTimepoint: Patients will be followed up: Weekly for 1 month Fortnightly for 4 months | — |
Countries
India
Contacts
Public ContactDr Hinal Jasvantbhai Prajapati
GMERS Medical College and Hospital
Outcome results
None listed